CA Patent

CA2936490C — Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children

Assigned to Mallinckrodt Pharmaceuticals Ireland Ltd · Expires 2022-10-04 · 4y expired

What this patent protects

The present invention provides a treatment of acute respiratory distress syndrome (ARDS) in children using dosing of nitric oxide at low concentrations, such as less than 10 ppm.

USPTO Abstract

The present invention provides a treatment of acute respiratory distress syndrome (ARDS) in children using dosing of nitric oxide at low concentrations, such as less than 10 ppm.

Drugs covered by this patent

Patent Metadata

Patent number
CA2936490C
Jurisdiction
CA
Classification
—
Expires
2022-10-04
Drug substance claim
No
Drug product claim
No
Assignee
Mallinckrodt Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.